Alterity Therapeutics (ATHE) Short term Debt (2011 - 2025)

Alterity Therapeutics has reported Short term Debt for 12 years, with the latest figure at $672518.3 in Q2 2025.

• On a quarterly basis, Short term Debt rose 453.2% year-over-year to $672518.3 in Q2 2025; TTM through Jun 2025 was $672518.3, a 453.2% increase from a year earlier, with the FY2025 full-year figure at $672518.3, up 453.2% from the prior year.
• Short term Debt was $672518.3 for Q2 2025 at Alterity Therapeutics, up from -$190408.0 in the prior quarter.
• The five-year high for Short term Debt was $19.5 million in Q2 2022, with the low at -$190408.0 in Q2 2024.
• Average Short term Debt over 5 years is $9.0 million, with a median of $9.3 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Short term Debt plunged 102.06% in 2024, then soared 453.2% in 2025.
• Over 5 years, Short term Debt stood at $15.8 million in 2021, then grew by 22.82% to $19.5 million in 2022, then slumped by 52.45% to $9.3 million in 2023, then slumped by 102.06% to -$190408.0 in 2024, then surged by 453.2% to $672518.3 in 2025.
• The last three Short term Debt figures came in at $672518.3 (Q2 2025), -$190408.0 (Q2 2024), and $9.3 million (Q2 2023), per Business Quant data.